Page 484 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Wilson 236 CaPSURE WW vs. RP 5.5 yr 4553 Newly diagnosed prostate Age: <55, 11%; 55-65, 33%; C
2007 vs. cancer patients identified within 65-75, 40%; >75, 16%
cryotherapy 6 months of diagnosis.
Retrospective vs. BT vs. PSA: NR
cohort EBRT vs. Additional inclusion criteria were
ADT vs. not reported; however, from the Gleason score: NR
descriptive statistics of the
population it appears that at Stage: NR
least some T3a patients were
included (the proportion is not
reported). For this reason, when
possible, we extracted data
(e.g., cost outcomes) only for
the subgroups of patients
classified as “low” or
“intermediate” risk, because
these subgroups do not include
T3a tumors (based on the study
definitions of risk categories).
th
ADT = androgen deprivation therapy; AS = active surveillance; BT = brachytherapy; CPT-4 = current procedural terminology, 4 edition; Dec. = December; Dif. = differentiated;
th
EBRT = external bean radiation therapy; HCPCS = Healthcare Common Procedure Coding System; ICD = International Classification of Diseases, 9 edition; IQR = interquartile
range; IV = instrumental variable; mo = months; NPCRSFS =National Cancer Register of Sweden Follow-up Study; NR = not reported; POCS = Patterns of Care Study;
PS = propensity score; PSA = prostate specific antigen; yr = year; RCT = randomized controlled trial; RP = radical prostatectomy; RT = radiation therapy; WW = watchful
waiting.

C-160